331 related articles for article (PubMed ID: 33167780)
1. Impact of baseline COPD symptom severity on the benefit from dual
Vogelmeier CF; Kerwin EM; Bjermer LH; Tombs L; Jones PW; Boucot IH; Naya IP; Lipson DA; Compton C; Barnes N; Maltais F
Ther Adv Respir Dis; 2020; 14():1753466620968500. PubMed ID: 33167780
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of umeclidinium/vilanterol according to the degree of reversibility of airflow limitation at screening: a post hoc analysis of the EMAX trial.
Vogelmeier CF; Jones PW; Kerwin EM; Boucot IH; Maltais F; Tombs L; Compton C; Lipson DA; Bjermer LH
Respir Res; 2021 Oct; 22(1):279. PubMed ID: 34711232
[TBL] [Abstract][Full Text] [Related]
3. Early and sustained symptom improvement with umeclidinium/vilanterol
Kerwin EM; Boucot IH; Vogelmeier CF; Maltais F; Naya IP; Tombs L; Jones PW; Lipson DA; Keeley T; Bjermer L
Ther Adv Respir Dis; 2020; 14():1753466620926949. PubMed ID: 32462979
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial.
Maltais F; Bjermer L; Kerwin EM; Jones PW; Watkins ML; Tombs L; Naya IP; Boucot IH; Lipson DA; Compton C; Vahdati-Bolouri M; Vogelmeier CF
Respir Res; 2019 Oct; 20(1):238. PubMed ID: 31666084
[TBL] [Abstract][Full Text] [Related]
5. The IMPACT Study - Single Inhaler Triple Therapy (FF/UMEC/VI) Versus FF/VI And UMEC/VI In Patients With COPD: Efficacy And Safety In A Japanese Population.
Kato M; Tomii K; Hashimoto K; Nezu Y; Ishii T; Jones CE; Kilbride S; Gross AS; Clifton CS; Lipson DA
Int J Chron Obstruct Pulmon Dis; 2019; 14():2849-2861. PubMed ID: 31839705
[TBL] [Abstract][Full Text] [Related]
6. A randomized, parallel-group study to evaluate the efficacy of umeclidinium/vilanterol 62.5/25 μg on health-related quality of life in patients with COPD.
Siler TM; Donald AC; O'Dell D; Church A; Fahy WA
Int J Chron Obstruct Pulmon Dis; 2016; 11():971-9. PubMed ID: 27274218
[TBL] [Abstract][Full Text] [Related]
7. Salbutamol use in relation to maintenance bronchodilator efficacy in COPD: a prospective subgroup analysis of the EMAX trial.
Maltais F; Naya IP; Vogelmeier CF; Boucot IH; Jones PW; Bjermer L; Tombs L; Compton C; Lipson DA; Kerwin EM
Respir Res; 2020 Oct; 21(1):280. PubMed ID: 33092591
[TBL] [Abstract][Full Text] [Related]
8. The effect of exacerbation history on outcomes in the IMPACT trial.
Halpin DMG; Dransfield MT; Han MK; Jones CE; Kilbride S; Lange P; Lipson DA; Lomas DA; Martinez FJ; Pascoe S; Singh D; Wise R; Criner GJ
Eur Respir J; 2020 May; 55(5):. PubMed ID: 32299860
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of once-daily inhaled umeclidinium/vilanterol in Asian patients with COPD: results from a randomized, placebo-controlled study.
Zheng J; Zhong N; Newlands A; Church A; Goh AH
Int J Chron Obstruct Pulmon Dis; 2015; 10():1753-67. PubMed ID: 26366068
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of umeclidinium/vilanterol for the management of patients with moderate to very severe COPD using an economic model.
Wilson MR; Patel JG; Coleman A; McDade CL; Stanford RH; Earnshaw SR
Int J Chron Obstruct Pulmon Dis; 2017; 12():997-1008. PubMed ID: 28392684
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of rescue medication use and medication adherence receiving umeclidinium/vilanterol versus tiotropium bromide/olodaterol.
Moretz C; Bengtson LG; Sharpsten L; Koep E; Le L; Tong J; Stanford RH; Hahn B; Ray R
Int J Chron Obstruct Pulmon Dis; 2019; 14():2047-2060. PubMed ID: 31564852
[TBL] [Abstract][Full Text] [Related]
12. Single-inhaler triple therapy utilizing the once-daily combination of fluticasone furoate, umeclidinium and vilanterol in the management of COPD: the current evidence base and future prospects.
Malerba M; Nardin M; Santini G; Mores N; Radaeli A; Montuschi P
Ther Adv Respir Dis; 2018; 12():1753466618760779. PubMed ID: 29537340
[TBL] [Abstract][Full Text] [Related]
13. Prevention of clinically important deteriorations in COPD with umeclidinium/vilanterol.
Singh D; Maleki-Yazdi MR; Tombs L; Iqbal A; Fahy WA; Naya I
Int J Chron Obstruct Pulmon Dis; 2016; 11():1413-24. PubMed ID: 27445468
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Umeclidinium/Vilanterol in Current and Former Smokers with COPD: A Prespecified Analysis of The EMAX Trial.
Bjermer LH; Boucot IH; Vogelmeier CF; Maltais F; Jones PW; Tombs L; Compton C; Lipson DA; Kerwin EM
Adv Ther; 2021 Sep; 38(9):4815-4835. PubMed ID: 34347255
[TBL] [Abstract][Full Text] [Related]
15. Evidence-based review of data on the combination inhaler umeclidinium/vilanterol in patients with COPD.
Albertson TE; Bowman WS; Harper RW; Godbout RM; Murin S
Int J Chron Obstruct Pulmon Dis; 2019; 14():1251-1265. PubMed ID: 31239659
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of FF/UMEC/VI compared with FF/VI and UMEC/VI in patients with COPD: subgroup analysis of the Spain cohort in IMPACT.
Marín JM; Mateos L; Roldán J; Echave-Sustaeta JM; Pascual-Guardia S; Pardo MV; Velasco B; Jones CE; Kilbride S; Lipson DA
Ther Adv Respir Dis; 2020; 14():1753466620963021. PubMed ID: 33121372
[TBL] [Abstract][Full Text] [Related]
17. Umeclidinium/vilanterol as step-up therapy from tiotropium in patients with moderate COPD: a randomized, parallel-group, 12-week study.
Kerwin EM; Kalberg CJ; Galkin DV; Zhu CQ; Church A; Riley JH; Fahy WA
Int J Chron Obstruct Pulmon Dis; 2017; 12():745-755. PubMed ID: 28280319
[TBL] [Abstract][Full Text] [Related]
18. Trelegy Ellipta--a three-drug inhaler for COPD.
Med Lett Drugs Ther; 2018 May; 60(1547):86-88. PubMed ID: 29913467
[No Abstract] [Full Text] [Related]
19. Spotlight on fluticasone furoate/umeclidinium/vilanterol in COPD: design, development, and potential place in therapy.
Lal C; Strange C
Int J Chron Obstruct Pulmon Dis; 2017; 12():135-140. PubMed ID: 28115838
[TBL] [Abstract][Full Text] [Related]
20. Relationship between exercise endurance and static hyperinflation in a post hoc analysis of two clinical trials in patients with COPD.
Singh S; Maltais F; Tombs L; Fahy WA; Vahdati-Bolouri M; Locantore N; Riley JH
Int J Chron Obstruct Pulmon Dis; 2018; 13():203-215. PubMed ID: 29386889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
